Search
Close
Search
Advanced Search
Search Menu

Abstract

While the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant cerebral edema is a potential adverse effect. Following are two clinical case reports demonstrating profound cerebral edema associated with implantation of Gliadel wafers. As a result, one of these individuals had premature death. A brief literature review is provided to assist in explaining the mechanisms by which clinically significant cerebral edema may develop.

References

Brem, H., Mahaley, M.S., Jr., Vick, N.A., Black, K.L., Schold, S.C., Jr., Burger, P.C., Friedman, A.H., Ciric, I.S., Eller, T.W., Cozzens, J.W., and Kenealy, J.N. (

1991
) Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas.
J. Neurosurg.
74
,
441
-446.

Brem, H., Tamargo, R.J., Olivi, A., Pinn, M., Weingart, J.D., Wharam, M. and Epstein, J.I. (

1994
) Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain.
J. Neurosurg.
80
,
283
-290.

Brem, H., Piantadosi, S., Burger, P.C., Walker, M., Selker, R., Vick, N.A., Black, K., Sisti, M., Brem, S., Mohr, G., Muller, P., Morawetz, R., and Schold, S.C. for the Polymer-Brain Tumor Treatment Group (

1995
) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas.
Lancet
345
(8956),
1008
-1012.

Dang, W.B., Daviau, T., Ying, P., Zhao, Y., Nowotnik, D., Clow, C.S., Tyler, B., and Brem, H. (

1996
) Effects of Gliadel wafer initial molecular weight on the erosion of wafer and release of BCNU.
J. Control. Release
42
(1),
83
-92.

Fleming, A.B., and Saltzman, W.M. (

2002
) Pharmacokinetics of the carmustine implant.
Clin. Pharmacokinet.
41
,
403
-419.

Fung, L.K., Shin, M., Tyler, B., Brem, H., and Saltzman, W.M. (

1996
) Chemotherapeutic drugs released from polymers: Distribution of 1,3-bis (2-chloroethyl)-1-nitrosourea in the rat brain.
Pharm. Res.
13
,
671
-682.

Giese, A., and Westphal, M. (

1996
) Glioma invasion in the central nervous system.
Neurosurgery
39
,
235
-250.

Grossman, S.A., Reinhard, C., Colvin, O.M., Chasin, M., Brundrett, R., Tamargo, R.J., and Brem, H. (

1992
) The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers.
J. Neurosurg.
76
,
640
-647.

Olivi, A., Grossman, S.A., Tatter, S., Barker, F., Judy, K., Olsen, J., Bruce, J., Hilt, D., Fisher, J., and Piantadosi, S. (

2003
) Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: A New Approaches to Brain Tumor Therapy CNS Consortium trial.
J. Clin. Oncol.
21
,
1845
-1849.

Reulen, H.J., Graham, R., Spatz, M., and Klatzo, I. (

1977
) Role of pressure gradients and bulk flow in dynamics of vasogenic brain edema.
J. Neurosurg.
46
,
24
-35.

Subach, B.R., Witham, T.F., Kondziolka, D., Lunsford, L.D., Bozik, M., and Schiff, D. (

1999
) Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: A retrospective case-matched cohort series.
Neurosurgery
45
,
17
-22.

Valtonen, S., Timonen, U., Toivanen, P., Kalimo, H., Kivipelto, L., Heiskanen, O., Unsqaard, G., and Kuurne, T. (

1997
) Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: A randomized double-blind study.
Neurosurgery
41
,
48
-49.

Westphal, M., Hilt, D.C., Bortey, E., Delavault, P., Olivares, R., Warnke, P.C., Whittle, I.R., Jaaskelainen, J., and Ram, Z. (

2003
) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.
Neuro-Oncol.
5
,
79
-88.

PDF
This content is only available as a PDF.
© 2005 by the Society for Neuro-Oncology
Topic:
Issue Section:
Surgical Neuro-Oncology
Download all slides